GL Pharm Tech

GL Pharm Tech EBITDA per Share

The EBITDA per Share of GL Pharm Tech (204840.KQ) as of Oct 19, 2026 is 16.89 KRW. In the previous year, EBITDA per Share was -30.54 KRW — a change of -155.31% (higher).

EBITDA per Share

16.89KRW

YoY

-155.31%

Last updated:

EBITDA per Share of GL Pharm Tech is 2025 16.89 KRW. EBITDA per Share of GL Pharm Tech was 2024 -30.54 KRW. It decreases by -155.31% higher compared to the previous year.

The GL Pharm Tech EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-128.53 KRW
Jan 1, 2019
-149.03 KRW
Jan 1, 2020
-71.59 KRW
Jan 1, 2021
-81.58 KRW
Jan 1, 2022
-85.10 KRW
Jan 1, 2023
-83.74 KRW
Jan 1, 2024
-30.54 KRW
Jan 1, 2025
16.89 KRW
The GL Pharm Tech EBITDA per Share history
YEAREBITDA per ShareYoY
16.89KRW-155.31%
-30.54KRW-63.53%
-83.74KRW-1.60%
-85.10KRW+4.31%
-81.58KRW+13.96%
-71.59KRW-51.96%
-149.03KRW+15.95%
-128.53KRW+1.37%
-126.79KRW+55.49%
-81.54KRW+3,711.77%
-2.14KRW-74.83%
-8.50KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GL Pharm Tech Stock analysis

What does GL Pharm Tech do? GL Pharm Tech Corp, based in Seongnam, South Korea, operates in the Health Care sector, specializing in pharmaceutical research and development services as well as the manufacturing and sale of pharmaceutical products. Listed on the stock market on 20 November 2014, the company focuses on developing and supplying pharmaceutical solutions within the Korean market. GL Pharm Tech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GL Pharm Tech stock

EBITDA per Share of GL Pharm Tech is 16.89 KRW in 2025.

EBITDA per Share of GL Pharm Tech changed from -30.54 KRW to 16.89 KRW, representing a -155.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share GL Pharm Tech since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — GL Pharm Tech

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — GL Pharm Tech